Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures
(World News USA)

Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the closing of the second tranche of the private placement of convertible debentures previously announced on November 23, 2016. The closing of this second tranche involved the sale of newly registered convertible debentures (convertible into 2,585,000 ordinary shares) for gross proceeds of $1,292,500. The Company received total net proceeds of $4,575,000 from both tranches of the private placement and a...